Advantages of the combined therapy with metformin and glimepiride in patients with type 2 diabetes mellitus
Full Text:PDF (Українська)
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79. doi: 10.2337/dc12-0413.
Abrahamson MJ. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well! Diabetes Care. 2015;38:160-169. doi: 10.2337/dc14-1945.
Inzucci SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-9. doi: 10.2337/dc14-2441.
Pankiv VI. Individual system of treatment of type 2 diabetes mellitus: when, whom and what alternative variants, except metformin. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2013;8(56):36-9. (in Ukrainian).
Pareek A, Chandurkar NB, Salkar HR. et al. Evaluation of Efficacy and Tolerability of Glimepiride and Metformin Combination: A Multicentric Study in Patients with Type-2 Diabetes Mellitus, Uncontrolled on Monotherapy with Sulfonylurea or Metformin. American Journal of Therapeutics. 2013 Jan;20(1):41-7. doi: 10.1097/MJT.0b013e3181ff7c63.
Nakamura I, Oyama J-I, Komoda H, Shiraki A, et al. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. Cardiovasc. Diabetol. 2014;13(15):1-8. doi: 10.1186%2F1475-2840-13-15.
Kravchun NA, Khyzhniak OO. Comparative analysis of application of glimepiride and prolonged action glyclazide in treatment of patients with type 2 diabetes mellitus. Problemy endokrynnoi patologii. 2010;1:5-11. (in Russian).
Charpentier G, Fleury F, Kabir M. et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients. Diabetic Medicine. 2001 Oct;18(10):828-34. doi: 10.1046/j.1464-5491.2001.00582.x.
Ivko TI, Germaniuk TA. Mathematical design as method of choice pharmacoecononic reasonable chart of the combined therapy of type 2 diabetes mellitus. Klinichna farmatsiya. 2015;19(3):30-36.(in Ukrainian).
Poltorak VV, Krasova NS, Gorshunskaya MY. Combined therapy of Metformin and Glimepiride in patients with type 2 diabetes mellitus (molecular mechanisms of optimization of vindicatory action). Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2015;1(65):87-97. (in Russian).
Korpacheva-Zinych OV, Lukashevych PY, Kushnareva NN, et al. Priority aspects of the glucose-lowering therapy in patients with type 2 diabetes: the interim results of the fist national multi-center study DіaDEYa (The study was conducted as part of the Ukrainian project to improve the quality of life in patients with type 2 diabetes mellitus). Endokrynologiya. 2016;21(4):287-302. (in Ukrainian).
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2019